|Bid||0.00 x 800|
|Ask||0.00 x 900|
|Day's Range||152.91 - 154.21|
|52 Week Range||125.79 - 154.46|
|PE Ratio (TTM)||75.93|
|Expense Ratio (net)||0.05%|
Value stocks are slipping as investors return to the growth style. Investors can also quickly capture broad growth segments of the market through targeted ETF strategies. Value stock ETFs are experiencing ...
There are dozens of large-cap value exchange-traded funds for value investors to consider. One of the most venerable is the Vanguard Value ETF (NYSE: VTV). VTV, which tracks the CRSP US Large Cap Value Index, is beloved among value investors for several reasons, not the least of which is its low fee.
If we dig into the S&P 500 and the S&P Growth indexes, we can see that they have the highest exposure to information technology (or IT). The S&P 500 Growth index generated a three-year and five-year annualized return of 13.2% and 15.2%, respectively. These returns compare to the S&P 500 (SPY) at 10.7% and 13% for the same timespan, respectively. The S&P 500 Growth index generated YTD (year-to-date) return of 5.5%, compared to the S&P 500 at 1.5%. The S&P 500 Growth has 41% exposure to information technology, compared to the S&P 500 at 24.8%. ...
Volatility and uncertainty have been playing foul in the U.S. stock market over the past couple of months. While the list of worries include higher rates, Washington turmoil, and tech selloff, the latest reason for the sluggish trading remains fears over a trade war between the United States and China.Source: Shutterstock
Although stocks have recently given back some of their short-term gains, the market big picture remains within the frame of momentum, which makes for a good environment to look to growth exchange-traded funds (ETFs).
AbbVie (ABBV) is focused on advancing its already strong position in the hematologic oncology segment in 2018. The overall hematologic malignancy and solid tumor market in the US is currently worth $87 billion and is expected to reach a market value of $169 billion by 2025. According to estimates from American Cancer Society, SEER, Kantar Health, IMS Institute Healthcare Informatics, Global Oncology Trend Report, and Evaluate Pharma, the total number of cancer patients worldwide is expected to reach 19 million by 2025.
Align Technology (ALGN) increased its expenditure toward consumer marketing by 60% in 2017. The increase in Invisalign treatment adoption rates across the teen and adult segments are driven by the company’s consumer marketing and sales initiatives. Peers Dentsply Sirona (XRAY), Zimmer Biomet Holdings (ZBH), and Henry Schein (HSIC) expect to post SG&A (selling, general, and administrative) expenses of 37.0%, 38.0%, and 20.0%, respectively, in their recent fiscal years.
Why is Vanguard voting against a shareholder measure on its proxy ballot that moves to stop investing in companies that "substantially contribute" to genocide?
This has been another year of brisk new product launches from the exchange-traded funds industry as hundreds of new funds have come to market. As is often the case, some new ETFs take awhile to attract ...
According to a Deloitte report, the biosimilars market is expected to grow to a market value of more than $445.0 billion by the end of 2019.
An activist group at Vanguard is asking shareholders to vote in favor of a proposal that would not allow the mutual fund giant to invest in companies that contribute to genocide or crimes against humanity. Yahoo Finance’s Alexis Christoforous, Ethan Wolff-Mann and Dan Roberts talk about why Vanguard is recommending its clients to vote against the proposal.